{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:25:19Z","timestamp":1781540719107,"version":"3.54.5"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2021,10,12]]},"DOI":"10.18632\/oncotarget.28090","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T12:41:17Z","timestamp":1633437677000},"page":"2114-2130","source":"Crossref","is-referenced-by-count":12,"title":["ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow\/MMRproficient cancer cells to temozolomide"],"prefix":"10.18632","volume":"12","author":[{"given":"Lara H.","family":"El Touny","sequence":"first","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"},{"name":"Current address: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Hose","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Connelly","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Harris","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Monks","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie B.","family":"Dull","sequence":"additional","affiliation":[{"name":"Clinical Pharmacodynamic Biomarkers Program, Applied\/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F.","family":"Wilsker","sequence":"additional","affiliation":[{"name":"Clinical Pharmacodynamic Biomarkers Program, Applied\/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda G.","family":"Hollingshead","sequence":"additional","affiliation":[{"name":"Biological Testing Branch, NCI, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gottholm-Ahalt","sequence":"additional","affiliation":[{"name":"Biological Testing Branch, NCI, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Y.","family":"Alcoser","sequence":"additional","affiliation":[{"name":"Biological Testing Branch, NCI, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Mullendore","sequence":"additional","affiliation":[{"name":"In Vivo Evaluation Program, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph E.","family":"Parchment","sequence":"additional","affiliation":[{"name":"Clinical Pharmacodynamic Biomarkers Program, Applied\/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA"},{"name":"Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly A.","family":"Teicher","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA"},{"name":"Molecular Pharmacology Branch, Developmental Therapeutics Program, NCI, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Rapisarda","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"35","author":"Ludwin","year":"2005","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"3","author":"Maio","year":"2013","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"e55665","DOI":"10.1371\/journal.pone.0055665","article-title":"Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage","volume":"8","author":"Kaina","year":"2013","journal-title":"PLoS One"},{"key":"4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1586\/era.12.37","article-title":"Molecular mechanisms of temozolomide resistance in glioblastoma multiforme","volume":"1","author":"Bjerkvig","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"1","author":"Samson","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/187152008784220276","article-title":"Role of mismatch repair and MGMT in response to anticancer therapies","volume":"8","author":"Bignami","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.dnarep.2016.05.008","article-title":"DNA damage tolerance by recombination: Molecular pathways and DNA structures","volume":"4","author":"Szakal","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"1","author":"Cimprich","year":"2014","journal-title":"Nat Cell Biol"},{"key":"9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs","volume":"5","author":"Fernandez-Capetillo","year":"2011","journal-title":"Mol Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner","volume":"7","author":"Brown","year":"2010","journal-title":"Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2016.10.023","article-title":"Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer","volume":"12","author":"Hammond","year":"2016","journal-title":"Radiother Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Wood","year":"2014","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/0008-5472.CAN-18-2807","article-title":"Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer","volume":"7","author":"Martineau","year":"2019","journal-title":"Cancer Res"},{"key":"14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"4","author":"Muschel","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"15","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1021\/acs.jmedchem.6b00596","article-title":"Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics","volume":"5","author":"Hadden","year":"2016","journal-title":"J Med Chem"},{"key":"16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT promoter methylation in malignant gliomas: ready for personalized medicine?","volume":"6","author":"Hegi","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.drudis.2015.02.011","article-title":"Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide","volume":"2","author":"Lagarce","year":"2015","journal-title":"Drug Discov Today"},{"key":"18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00280-009-1078-6","article-title":"Evaluation of the exposure equivalence of oral versus intravenous temozolomide","volume":"6","author":"Ottaviano","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1101\/gad.294404","article-title":"Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase","volume":"1","author":"Jiricny","year":"2004","journal-title":"Genes Dev"},{"key":"20","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1158\/1535-7163.MCT-13-0136","article-title":"Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide","volume":"1","author":"Kaina","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors","volume":"7","author":"Bindra","year":"2019","journal-title":"Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-10-3082","article-title":"Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition","volume":"1","author":"Zabludoff","year":"2011","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 Kinase in Cancer","volume":"3","author":"Reigan","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.dnarep.2008.09.003","article-title":"Brca2\/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs","volume":"8","author":"Kaina","year":"2009","journal-title":"DNA Repair (Amst)"},{"key":"25","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"1","author":"Jasin","year":"1999","journal-title":"Genes Dev"},{"key":"26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fonc.2014.00289","article-title":"A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin","volume":"4","author":"Shmookler Reis","year":"2014","journal-title":"Front Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","article-title":"Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells","volume":"8","author":"Maybaum","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"28","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"3","author":"van Vugt","year":"2015","journal-title":"Oncogene"},{"key":"29","doi-asserted-by":"publisher","first-page":"38244","DOI":"10.1074\/jbc.M608369200","article-title":"Translesion synthesis across O6-alkylguanine DNA adducts by recombinant human DNA polymerases","volume":"28","author":"Guengerich","year":"2006","journal-title":"J Biol Chem"},{"key":"30","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-15-1884","article-title":"The Error-Prone DNA Polymerase \u03ba Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling","volume":"7","author":"Wang","year":"2016","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/0008-5472.CAN-14-0953","article-title":"Translesion polymerase \u03b7 is upregulated by cancer therapeutics and confers anticancer drug resistance","volume":"7","author":"Christmann","year":"2014","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1215\/15228517-2009-015","article-title":"REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy","volume":"1","author":"Chen","year":"2009","journal-title":"Neuro Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"e0120334","DOI":"10.1371\/journal.pone.0120334","article-title":"REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells","volume":"1","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"key":"34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/jid.2010.310","article-title":"siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide","volume":"13","author":"Ribas","year":"2011","journal-title":"J Invest Dermatol"},{"key":"35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"1","author":"Bell-McGuinn","year":"2017","journal-title":"Lancet Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"8013575","DOI":"10.1155\/2017\/8013575","article-title":"Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives","volume":"201","author":"Kaspera","year":"2017","journal-title":"Biomed Res Int"},{"key":"37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","article-title":"Temozolomide in the Era of Precision Medicine","volume":"7","author":"Pommier","year":"2017","journal-title":"Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/0008-5472.CAN-16-1151","article-title":"DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme","volume":"7","author":"Samson","year":"2017","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2012.07781.x","article-title":"Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells","volume":"12","author":"Weller","year":"2012","journal-title":"J Neurochem"},{"key":"40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1541-7786.MCR-16-0125","article-title":"Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma","volume":"1","author":"Burma","year":"2016","journal-title":"Mol Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1016\/j.celrep.2016.12.031","article-title":"Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities","volume":"1","author":"Berglund","year":"2016","journal-title":"Cell Rep"},{"key":"42","doi-asserted-by":"publisher","first-page":"8440","DOI":"10.1093\/nar\/gks646","article-title":"CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation","volume":"4","author":"Helleday","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/mol.107.044743","article-title":"AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition","volume":"7","author":"D'Atri","year":"2008","journal-title":"Mol Pharmacol"},{"key":"44","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1124\/mol.111.076828","article-title":"DNA polymerase \u03b6 is a major determinant of resistance to platinum-based chemotherapeutic agents","volume":"8","author":"Canman","year":"2012","journal-title":"Mol Pharmacol"},{"key":"45","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/jcp.25792","article-title":"Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells","volume":"23","author":"Li","year":"2017","journal-title":"J Cell Physiol"},{"key":"46","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.molonc.2014.07.008","article-title":"Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress","volume":"8","author":"Marti","year":"2014","journal-title":"Mol Oncol"},{"key":"47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Goldberg","year":"2012","journal-title":"Cancer Discov"},{"key":"48","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1158\/1535-7163.MCT-08-0921","article-title":"DNA fingerprinting of the NCI-60 cell line panel","volume":"8","author":"Weinstein","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"49","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"8","author":"Boyd","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"50","doi-asserted-by":"publisher","first-page":"B24","DOI":"10.1158\/1557-3125.Cellcycle16-B24","article-title":"Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models","volume":"1","author":"Kinders","year":"2016","journal-title":"Mol Cancer Res"},{"key":"51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1472-6750-11-124","article-title":"Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts","volume":"1","author":"Hollingshead","year":"2011","journal-title":"BMC Biotechnol"},{"key":"52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/a:1006313611677","article-title":"UCN-01 enhances thetoxicity of clinical agents in human tumor cell lines","volume":"1","author":"Sausville","year":"2000","journal-title":"Invest New Drugs"},{"key":"53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2017.06.022","article-title":"Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies","volume":"14","author":"Prichard","year":"2017","journal-title":"Antiviral Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:08:15Z","timestamp":1634087295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":53,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,10,12]]}},"alternative-id":["28090"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28090","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}